ZKB/PUT/ELI LILLY & CO/710/0.01/27.09.24 | Market Closed - Swiss Exchange 11:20:00 2024-07-10 am EDT | ||
| 0.04 CHF | -11.11% |
|
| Current month | -27.27% | ||
| 1 month | -60.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 0.04 | -11.11% |
| 24-07-09 | 0.045 | -10.00% |
| 24-07-08 | 0.05 | -9.09% |
| 24-07-05 | 0.055 | -8.33% |
| 24-07-03 | 0.06 | +20.00% |
Delayed Quote Swiss Exchange
Last update July 10, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| LLYGFZ | |
| ISIN | CH1305145109 |
| Date issued | 2024-03-14 |
| Strike | 710 $ |
| Maturity | 2024-09-27 (77 Days) |
| Parity | 100 : 1 |
| Emission price | 0.43 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.48 CHF |
|---|---|
| Lowest since issue | 0.04 CHF |
| Spread | 0.01 CHF |
| Spread % | 25.00% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4
USD
Average target price
894.8
USD
Spread / Average Target
-5.65%
- Stock Market
- Warrants
- LLYGFZ Warrant
